Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers

Next Previous
Trial Profile

A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OC-001 (Primary) ; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Ocellaris Pharma

Most Recent Events

  • 12 Jan 2026 Status changed from active, no longer recruiting to discontinued.
  • 23 Dec 2025 Status changed from recruiting to active, no longer recruiting.
  • 27 Nov 2023 Planned End Date changed from 1 Nov 2022 to 30 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top